Most Recent Articles about Amgen
The Daily Biotech Pulse: Revance Common Stock Offering, Adcom Catalyst For Amgen http://feeds.benzinga.com/~r/benzinga/~3/-qf8Lb6Vq5o/the-daily-biotech-pulse-revance-common-stock-offering-adcom-catalyst- Jan 16, 2019 -

Here's a roundup of top developments in the biotech space over the last 24 hours.

Scaling The Peak

(Biotech Stocks Hitting 52-week highs Jan. 15)

read more

For Children With Cancer, Hope for New Treatments https://www.wsj.com/articles/for-children-with-cancer-hope-for-new-treatments-11547561004?mod=WSJ_GoogleNews Jan 16, 2019 - A new law requiring pharmaceuticals companies to test cancer drugs on children as well as adults is raising hopes of more therapies.
Why AbbVie Believes In Life After (Humira's) Death https://seekingalpha.com/article/4233472-abbvie-believes-life-humiras-death?source=feed_sector_healthcare Jan 15, 2019 - ABBV has been mired in a bear market, in large part due to worse-than-expected competition to Humira from biosimilars in the EU.U.S. biosimilars to Humira will enter in 2023, though a competitor is tr

Related Companies

Name Exchange Price Mkt Cap
GILD Gilead Sciences, Inc. NASDAQ $72.78 $94.35B
BIIB Biogen Inc. NASDAQ $334.44 $67.37B
SGEN Seattle Genetics, Inc. NASDAQ $76.15 $12.09B
NBIX Neurocrine Biosciences, Inc. NASDAQ $117.38 $10.62B
QGEN Qiagen N.V. NASDAQ $37.42 $8.5B
Sector: Health Care > Industry: Biotechnology: Biological Products (No Diagnostic Substances)